Saturday, 31 October 2026European Markets

BELSHIPS And NEXANS Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(vianews) - belships (belco.ol) is among this list of stock assets with the highest dividend rate and return on equity on the industrials sector.

financial asset price forward dividend yield return on equity
belships (belco.ol) kr17.58 16.26% 50.41%
nexans (nex.pa) €76.35 2.86% 11.49%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. belships (belco.ol)

16.26% forward dividend yield and 50.41% return on equity

belships asa owns and operates dry bulk ships worldwide. it operates through own ships, lighthouse naviagtion, and ship management segments. the company operates a fleet of 34 supra/ultramax bulk carriers. it also provides commercial and ship management, technical, crewing, port agency, and logistical services. the company was founded in 1918 and is headquartered in oslo, norway.

earnings per share

as for profitability, belships has a trailing twelve months eps of kr4.13.

pe ratio

belships has a trailing twelve months price to earnings ratio of 4.26. meaning, the purchaser of the share is investing kr4.26 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.41%.

more news about belships.

2. nexans (nex.pa)

2.86% forward dividend yield and 11.49% return on equity

nexans s.a. designs, manufactures, and sells cable systems and services in france and internationally. it operates in five segments: building & territories, generation & transmission, telecom & data, industry & solutions, and other activities. the company provides design, engineering, financing, asset management, and systems management solutions for offshore wind farms, subsea interconnections, and land high voltage, as well as smart solutions for oil and gas sector. it also offers cables for the energy distribution networks; and equipment cables for buildings. in addition, the company provides cabling and connectivity solutions to support oems and industrial infrastructure project managers in transport, automatic devices, renewable energy, resources, and other sectors. further, it offers data transmission, telecom networks, hyperscale data centers, and lan cabling solutions for customers to deploy copper and fiber optic infrastructures; and wire rods and electrical wires, as well as engages in winding wire production operations. the company was incorporated in 1994 and is headquartered in courbevoie, france.

earnings per share

as for profitability, nexans has a trailing twelve months eps of €5.46.

pe ratio

nexans has a trailing twelve months price to earnings ratio of 13.98. meaning, the purchaser of the share is investing €13.98 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.49%.

revenue growth

year-on-year quarterly revenue growth declined by 7.7%, now sitting on 8.04b for the twelve trailing months.

yearly top and bottom value

nexans's stock is valued at €76.35 at 17:30 est, way below its 52-week high of €102.90 and above its 52-week low of €70.10.

more news about nexans.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com